2025 Japan Artificial Intelligence (Ai) In Drug Discovery Market Revenue Opportunities Report
Description
The 2025 Japan Artificial Intelligence (Ai) In Drug Discovery Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Artificial Intelligence (AI) in Drug Discovery Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the AI-driven drug discovery market in Japan include Elix, Astellas Pharma, Daiichi Sankyo, and SoftBank Group. Elix, Tokyo-based and founded in 2016, has developed an AI platform using federated learning trained on confidential pharmaceutical data from many Japanese pharma companies and research institutions like RIKEN and Kyoto University, enhancing target prediction, ADMET profiling, and compound generation. Astellas Pharma leverages NVIDIA’s BioNeMo AI platform to accelerate biologics research by generating and optimizing molecular structures, achieving over 30x faster chemical molecule generation. Daiichi Sankyo also uses NVIDIA’s Tokyo-1 AI supercomputer to advance drug discovery through AI modeling and molecular simulations. SoftBank Group invests heavily in AI, partnering with OpenAI through SB OpenAI Japan, aiming to deploy advanced AI agents across subsidiaries and contribute substantially to AI infrastructure, supporting next-generation AI applications in drug discovery.
These companies exemplify Japan's strategic focus on integrating AI to reduce drug development time and cost while improving success rates. Elix’s technical collaboration with prestigious universities and its use of federated learning preserve data confidentiality while achieving predictive accuracy. Astellas and Daiichi Sankyo utilize advanced AI supercomputing for biological and chemical simulations, pushing frontier drug research. SoftBank's investments and global partnerships underline Japan's ambition to lead in AI infrastructure, enhancing drug discovery and related sectors. Collectively, they reflect Japan's governmental support and industry cooperation to strengthen AI in pharmaceutical R&D, addressing challenges like lengthy development timelines and high costs.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Artificial Intelligence (AI) in Drug Discovery Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the AI-driven drug discovery market in Japan include Elix, Astellas Pharma, Daiichi Sankyo, and SoftBank Group. Elix, Tokyo-based and founded in 2016, has developed an AI platform using federated learning trained on confidential pharmaceutical data from many Japanese pharma companies and research institutions like RIKEN and Kyoto University, enhancing target prediction, ADMET profiling, and compound generation. Astellas Pharma leverages NVIDIA’s BioNeMo AI platform to accelerate biologics research by generating and optimizing molecular structures, achieving over 30x faster chemical molecule generation. Daiichi Sankyo also uses NVIDIA’s Tokyo-1 AI supercomputer to advance drug discovery through AI modeling and molecular simulations. SoftBank Group invests heavily in AI, partnering with OpenAI through SB OpenAI Japan, aiming to deploy advanced AI agents across subsidiaries and contribute substantially to AI infrastructure, supporting next-generation AI applications in drug discovery.
These companies exemplify Japan's strategic focus on integrating AI to reduce drug development time and cost while improving success rates. Elix’s technical collaboration with prestigious universities and its use of federated learning preserve data confidentiality while achieving predictive accuracy. Astellas and Daiichi Sankyo utilize advanced AI supercomputing for biological and chemical simulations, pushing frontier drug research. SoftBank's investments and global partnerships underline Japan's ambition to lead in AI infrastructure, enhancing drug discovery and related sectors. Collectively, they reflect Japan's governmental support and industry cooperation to strengthen AI in pharmaceutical R&D, addressing challenges like lengthy development timelines and high costs.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
